How did AtaiBeckley's stock react to the acquisition news?

AtaiBeckley shares surged 33% on July 16, 2026.

What psychedelic drugs does AtaiBeckley develop?

AtaiBeckley focuses on psilocybin and MDMA-based therapies for depression and PTSD.

Has the FDA approved any psychedelic drug so far?

No, the FDA has not yet approved any psychedelic-based treatment, posing a regulatory challenge for the deal.

Eli Lilly Acquires AtaiBeckley for Up to $3.8B in Psychedelics Push

Eli Lilly (LLY) announced the acquisition of AtaiBeckley, a clinical-stage psychedelics developer, in a cash deal worth up to $3.8 billion. AtaiBeckley shares surged 33% on the news.

July 16, 2026

2 min read

Source: Motley Fool

Key Numbers

deal value

3.8B

stock jump

33%

Eli Lilly (NYSE: LLY) announced today, July 16, 2026, the acquisition of AtaiBeckley, a clinical-stage psychedelics developer, in a cash deal valued at up to $3.8 billion. AtaiBeckley shares jumped 33% following the announcement.

Deal Details

Item	Details
Total Value	Up to $3.8 billion
Payment Method	All cash
Upfront Payment	Not disclosed
Milestone Payments	Tied to development and regulatory milestones
Acquired Company	AtaiBeckley (ticker not specified)
Acquirer	Eli Lilly (LLY)

Rationale

The acquisition aligns with Eli Lilly's strategy to expand into mental health, particularly as psychedelic compounds gain traction for treating depression and PTSD. AtaiBeckley has a pipeline of psilocybin and MDMA-based therapies in various stages of development.

Regulatory Challenges

Psychedelic drugs face significant regulatory hurdles, with no FDA-approved treatments yet. The approval process could be lengthy and require additional clinical trials.

Impact on Stocks

AtaiBeckley shares rose 33% in today's trading, while Eli Lilly shares remained relatively flat. Analysts view the deal as a long-term growth opportunity for Lilly in mental health, but regulatory risks persist.

Frequently Asked Questions

The deal is valued at up to $3.8 billion, including an upfront cash payment and milestone payments tied to development achievements.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.